Showing results (21-30 of 42) with videos related to
Sort By:
Pageof 5
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|February 2, 2013
Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virusSarah Maylin, Anders Boyd, Michelle Martinot-Peignoux, et al.Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 6, 2013
Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNAMichelle Martinot-Peignoux, Martine Lapalus, Cédric Laouénan, et al.Romanian Journal of Gastroenterology|July 30, 2002
Role of cytokines in the assessment of the severity of chronic hepatitis C and the prediction of response to therapyManuela G Neuman, Jean-Pierre Benhamou, Asma Ibrahim, et al.Hepatology (Baltimore, Md.)|August 31, 2006
Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-upCorinne Castelnau, Frédéric Le Gal, Marie-Pierre Ripault, et al.Antiviral Therapy|December 25, 2009
Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2aRami Moucari, Michelle Martinot-Peignoux, Vincent Mackiewicz, et al.Journal of Virology|March 28, 2014
Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis CEmilie Estrabaud, Martine Lapalus, Philippe Broët, et al.Liver International : Official Journal of the International Association for the Study of the Liver|December 17, 2008
Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibodySarah Maylin, Michelle Martinot-Peignoux, Marie-Pierre Ripault, et al.Hepatology (Baltimore, Md.)|January 14, 2010
Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirinMichelle Martinot-Peignoux, Christiane Stern, Sarah Maylin, et al.Antiviral Therapy|July 7, 2009
Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirinMichelle Martinot-Peignoux, Sarah Maylin, Rami Moucari, et al.Hepatology (Baltimore, Md.)|December 31, 2008
Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patientsRami Moucari, Vincent Mackiewicz, Olivier Lada, et al.Pageof 5